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Abstract
Rationale Treatment of attention-deficit/hyperactivity disor-
der (ADHD) has for many years relied on psychostimulants,
particularly various formulations of amphetamines and
methylphenidate. These are central nervous system stimu-
lants and are scheduled because of their abuse potential.
Atomoxetine (atomoxetine hydrochloride; Strattera®) was
approved in 2002 for treatment of ADHD, and was the first
nonstimulant medication approved for this disorder. It was
classified as an unscheduled medication indicating a low
potential for abuse. However, the abuse potential of atom-
oxetine has not been reviewed.
Objectives In this article, we review the evidence regarding
abuse potential of atomoxetine, a selective inhibitor of the
presynaptic norepinephrine transporter, which is unschedu-
led/unrestricted in all countries where it is approved.
Methods Results from receptor binding, in vitro electro-
physiology, in vivo microdialysis, preclinical behavioral,
and human laboratory studies have been reviewed.
Results Atomoxetine has no appreciable affinity for, or ac-
tion at, central receptors through which drugs of abuse
typically act, i.e., dopamine transporters, GABAA receptors,
and opioid μ receptors. In behavioral experiments in
rodents, atomoxetine does not increase locomotor activity,
and in drug discrimination studies, its profile is similar to
that of drugs without abuse potential. Atomoxetine does not
serve as a reinforcer in monkey self-administration studies,
and human laboratory studies suggest that atomoxetine does
not induce subjective effects indicative of abuse.
Conclusion Neurochemical, preclinical, and early clinical
studies predicted and supported a lack of abuse potential of
atomoxetine, which is consistent with the clinical trial and
postmarketing spontaneous event data in the past 10 years.
Keywords Atomoxetine (Strattera®) . ADHD . Abuse
potential . Nonstimulant
Introduction
Attention-deficit/hyperactivity disorder (ADHD) (APA
2000) is an early onset childhood disorder that is estimated
to occur in 3 % to 9 % of children and adolescents in the
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USA (Faraone et al. 2003; Greydanus et al. 2007) and 4 %
to 8 % worldwide (Kessler et al. 2006; Smoot et al. 2007).
Frequently associated with impaired academic and social
functioning, ADHD persists into adulthood in 50 % to
70 % of affected youth (Barkley et al. 2002; Hechtman
2000). For decades, management of ADHD relied primarily
on psychostimulants, such as amphetamines and methylphe-
nidate, for which short- and long-acting formulations are
available through a wide variety of branded and generic
manufacturers. Although their efficacy is well documented,
psychostimulants are controlled substances because of their
documented abuse potentials. Amphetamines and methyl-
phenidate are currently classified as schedule II drugs by the
US Controlled Substance Act (CSA), indicating that while
they have an approved medical use, they also have signifi-
cant abuse liabilities, which raises concerns about nonmed-
ical use in patients with ADHD, including misuse, abuse, or
diversion to individuals without ADHD (Substance Abuse
and Mental Health Services Administration 2006; The
National Center on Addiction and Substance Abuse at
Columbia University 2007). A wide range of drug classes
are subject to regulation under the CSA including central
nervous system depressants and stimulants. CSA requires an
eight-factor analysis for all scheduling decisions by the
Drug Enforcement Administration (http://www.fda.gov/
d own l o a d s /Abou t FDA /Cen t e r sO f f i c e s /CDER /
UCM180870.pdf). This analysis includes factors such as its
actual or relative potential for abuse; pharmacological effect;
other current scientific knowledge; history and current pattern
of abuse; scope, duration, and significance of abuse; public
health risk; psychic or physiological dependence potential;
and if the drug is an immediate precursor of a controlled
substance under section 21 USC 811(c). Scheduling of a drug
regulated under CSA can influence prescribing, utilization,
and manufacturing requirements of that drug.
Atomoxetine is a selective inhibitor of the presynaptic
norepinephrine (NE) transporter, with minimal affinity for
noradrenergic receptors or other neurotransmitter transporters
or receptors (Bymaster et al. 2002). In 2002, it was approved
by the US Food and Drug Administration (FDA) as an uncon-
trolled, nonstimulant treatment for pediatric, adolescent, and
adult ADHD (Michelson et al. 2002, 2003; Spencer et al. 1998,
2002). Atomoxetine has been shown to be efficacious for the
treatment of ADHD with a favorable safety profile (Simpson
and Plosker 2004; Garnock-Jones and Keating 2010).
Recently, extended release formulations of two nonsti-
mulant α(2A)-adrenoceptor agonists guanfacine and cloni-
dine, have been approved in the USA for the treatment of
ADHD in children and adolescents. Like atomoxetine, both




In addition to concerns regarding diversion of prescribed
medications, treatment of patients with ADHD, especially
adolescents and adults, is complicated by their high comor-
bidity for substance use disorders (Biederman et al. 1997;
Molina and Pelham 2003; Shekim et al. 1990; Upadhyaya et
al. 2005; Wilens et al. 1997). Its effect on neurobiological
pathways suggests that atomoxetine has less abuse potential
than stimulants (Wee and Woolverton 2004) due to its lack
of increase of dopamine (DA) transmission in the mesolim-
bic and mesocortical pathways up to the nucleus accumbens
(NAc) (Bymaster et al. 2002; Simpson and Plosker 2004).
Previous reviews have demonstrated that atomoxetine is
useful for patients at risk of substance abuse or who do
not wish to take a controlled substance: atomoxetine is
effective, has a favorable safety profile, and has a negligible
risk of abuse or misuse (Garnock-Jones and Keating 2010;
Simpson and Plosker 2004). However, a comprehensive
review of abuse potential assessments of atomoxetine com-
pared with psychostimulant drugs has not been published. In
this review article, we review previously published literature
on abuse potential testing for atomoxetine and present re-
search findings that demonstrate the low abuse potential of
atomoxetine in contrast to psychostimulant medications,
such as amphetamine and methylphenidate.
Neurobiology of stimulant action
The mesolimbic and mesocortical pathways, both part of the
brain reward circuitries, connect the structures that are
thought to control and regulate stimulant activity and be-
havior. The mesolimbic system extends from the ventral
tegmental area via the medial forebrain bundle to the NAc,
which is the primary release site for DA (Koob 1992).
Amphetamines and methylphenidate have similar effects
on DA and NE neurotransmission (Kahlig et al. 2005;
Simpson and Plosker 2004). Both substances primarily in-
crease DA and, to a lesser degree, noradrenergic activity in
neural systems. Both block presynaptic reuptake of DA,
resulting in higher synaptic levels, as suggested by micro-
dialysis studies (Bredeloux et al. 2007; Bymaster et al.
2002; Koda et al. 2010; Mazei et al. 2002; Pontieri et al.
1995). Amphetamine also causes nonvesicular release of
DA through the dopamine transporter (DAT) by promoting
the exchange for cytosolic DA (Partilla et al. 2006;
Sandoval et al. 2002). Amphetamine causes DAT-mediated
DA efflux by two independent mechanisms: (1) a slow
process consistent with an exchange mechanism and (2) a
process that results in rapid (milliseconds) bursts of DA
efflux that is comparable to transport through a channel
such as DAT. This rapid release of large numbers of DA
molecules plays a role in the synaptic actions and psychos-
timulant effects of amphetamine and related compounds
(Kahlig et al. 2005).
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Therapeutic doses of oral methylphenidate can effective-
ly block DATs (Volkow et al. 1998) and significantly in-
crease extracellular DA (Volkow et al. 2001) in humans. An
evaluation of the levels of DAT blockade is important in
light of the evidence that DATs are involved in mediating
the reinforcing effects of cocaine (Ritz et al. 1987). Volkow
et al. (1997) demonstrated that the extent and time course of
DAT occupancy in human volunteers who abuse cocaine
correlated with the “high” subjective effect of cocaine. A
review of its clinical use and abuse indicated that reinforcing
effects of methylphenidate may be attributed to large and
rapid increases in extracellular DA, whereas therapeutic
effects occur when the drug elicits slow, steady-state DA
increase (Volkow and Swanson 2003).
Evidence for abuse potential of stimulants
Prevalence rates Comprehensive reviews on this subject are
provided in the publications by Kollins (2007) and Wilens et
al. (2008a). In 2005, the Drug Abuse Warning Network
(Subs tance Abuse and Menta l Heal th Serv ices
Administration 2007) estimated that stimulants, including
amphetamines, were involved in 138,950 emergency depart-
ment visits; the rates were highest among patients 18 to
44 years old. Further, the annual prevalence rate for amphet-
amine use among US 12th graders was reported to be 8.2 %
in 2011 (Johnston et al. 2012). The trend of amphetamine
use among college students has increased from 4.2 % in
1996 to 9.0 % in 2010 (Johnston et al. 2009, 2011). Further,
the annual prevalence rates for methylphenidate use in 8th,
10th, and 12th graders was reported to be 1.6 %, 2.9 %, and
3.4 %, respectively (Johnston et al. 2008). While among
college-aged students, the prevalence of illicit methylpheni-
date use was 4.2 % in 2005 (Johnston et al. 2009).
A study based on Internet-based epidemiological survey
evaluated the prevalence of nonmedical use of prescription
medications for ADHD (Novak et al. 2007). This study
reported that ~7.01 % of US adults aged 18–49 years used
a stimulant ADHD medication for nonmedical purpose at
least once in their lifetime. The prevalence of nonmedical
use was more for short-acting stimulants versus long-acting
ones. Although the original study reported productivity as
the most frequent reason for nonmedical use of ADHD
medication (Novak et al. 2007), a post hoc analysis revealed
that a substantial proportion of young adults may be using
stimulants for self-medication of ADHD symptoms
(Upadhyaya et al. 2010). The motivation for nonmedical
use of immediate- and extended-release formulations of
stimulants may be distinct, such as recreational versus
productivity. Irrespective of the intended nonmedical
use, friends and family remain an important source for
diverted medication (Novak et al. 2007; Upadhyaya et
al. 2010).
Adverse effects Adverse events related to various forms of
amphetamines include abuse, dependence, and neurotoxici-
ty. Evidence indicates that the adverse effects observed
in humans and experimental animals can be explained
by the critical role of amphetamines on DA and NE.
These include arousal, hyperactivity, stereotypic persev-
erative movements, psychomotor depression, cognitive
impairment, hallucinatory-like behaviors, and chronic
self-administration (Berman et al. 2009). Chronic ad-
ministration has also shown neurotoxicity that can per-
sist for years, such as deficits in phenotypic markers for
dopaminergic nerve terminals, enlarged chromatolytic
medulla neurons in cats, and swollen or reduced dopa-
minergic axons, and serotonin deficits in rodents
(Berman et al. 2009).
Self-administration, reinforcing, and subjective effects
Human abuse potential has been well predicted through the
animal self-administration model paradigms. Methylphenidate
was self-administered by nonhuman primates (Bergman et al.
1989; Johanson and Schuster 1975; Wilson et al. 1971) and
humans (Jasinski et al. 2008). In a human laboratory study
(Jasinski et al. 2008), methylphenidate produced significant
positive effects and drug-liking. Both intranasal (Garland
1998; Massello and Carpenter 1999) and intravenous (Parran
and Jasinski 1991) use of methylphenidate have also
been reported. This is further confirmed by the results
of a placebo-controlled human laboratory study that
examined the reinforcing and subjective effects of meth-
ylphenidate and D-amphetamine in non-drug-abusing
subjects (Rush et al. 2001). It was demonstrated that
methylphenidate and D-amphetamine could function as
reinforcers and produce stimulant-like subjective effects,
leading to abuse potential. Both drugs produced compa-
rable subject-rated drug effects, including increased A scores
on the Addiction Research Center Inventory (ARCI), in-
creased ratings of “any effect” and “like drug” on the
subject-rated drug-effect questionnaire. Although, in this
study the reinforcing and subject-rated drug effects with meth-
ylphenidate were observed only at the highest dose tested
(40 mg), this did not undermine its drug abuse potential.
Thus, the existing evidence, including surveys and controlled
laboratory conditions, indicates that amphetamines and meth-
ylphenidate have significant abuse potential.
Atomoxetine: lack of evidence for abuse potential
Various biochemical, pharmacological (e.g., receptor bind-
ing, in vivo microdialysis), and behavioral studies in ani-
mals, and human studies that measured the subjective
effects of atomoxetine have been conducted to assess its
potential for abuse potential. Stimulant-induced increases in
extracellular DA levels, especially in the NAc, plays an
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important role in their drug abuse potential, and therefore,
atomoxetine was examined for its effect on extracellular
levels in the NAc as well as various neuronal receptor
activities. The methods and results of these studies are
described in the following sections.
Receptor binding studies
Receptor-binding studies may be used to determine the
binding affinity of an active substance to known targets
involved in drug dependence (e.g., opioid receptors, 5-HT,
and dopamine transporters and receptors, NMDA, GABA,
nicotinic acetylcholine, and cannabinoid receptors). The
agonist or antagonist effects of binding to a receptor can
be determined by functional assays at the cellular level.
Studies assessing the affinity and functional effects of atom-
oxetine on target receptors are presented below.
The inhibition constant (Ki values, lower values indi-
cate greater affinity) of atomoxetine for binding of
ligands to monoamine uptake transporters (Bymaster et
al. 2002) was Ki=5.4 nM for the human NE transporter,
Ki=87 nM for human serotonin (5-HT; see section “In
vivo animal studies”), and Ki =1451 nM for DATs.
Atomoxetine also has a low affinity for a number of
other binding sites, suggesting selectivity for the NE
transporter. In contrast, methylphenidate has higher affinity
for the human DA transporter (Ki=34 nM) than for the NE
transporter (Ki=339 nM). The binding affinities of atomoxe-
tine and other agents for the DA and NE transporter, compiled
from several publications, are provided in Table 1. The ratio of
Ki values for DA and NE transporters reveals that several
nonscheduled drugs, including atomoxetine, have much
higher ratio values compared with scheduled stimulants
(methylphenidate, D-amphetamine, and cocaine), whose ratios
are less than 1.0. In contrast, the ratio for atomoxetine is 342,
indicating much higher affinity for the NE than DA transport-
er and therefore suggesting a lower potential for DA-mediated
substance abuse.
In addition, the binding affinity and functional activity of
atomoxetine and its major metabolite, 4-hydroxyatomoxetine,
was assessed at 63 neuronal receptors and binding sites,
including neurotransmitter receptor sites such as the opioid
μ receptor, second messengers, ion channels, transporters, and
brain and gut peptides (Bymaster et al. 2002). Atomoxetine at
1μMdid not inhibit any of these receptors bymore than 50%,
except binding to opioid σ1 receptor, which was inhibited by
51.4 %. The 4-hydroxyatomoxetine metabolite (1 μM)
inhibited radioligand binding to opioid δ1, κ1, and μ recep-
tors by 52 %, 59 %, and 66 %, respectively. In a separate
experiment, 4-hydroxyatomoxetine was found to have rela-
tively low affinity for these same three receptors, with Ki
values of 300 nM, 95 nM, and 422 nM, respectively
(Bymaster et al. 2002).
Electrophysiological studies
Drugs with abuse potential include sedative/hypnotic drugs,
whose mechanism of action are thought to involve the
agonistic action on γ-aminobutyric acid (GABAA) receptors
(Bergman et al. 2000). Although atomoxetine had low af-
finity for GABAA and benzodiazepine receptors in binding
studies (Bymaster et al. 2002), the potential actions of atom-
oxetine on GABAA receptors were further evaluated using
electrophysiological recording of GABAA receptor-
dependent activity of ventrobasal thalamic relay neurons in
a rat brain slice preparation (Zhang et al. 1997).
The possibility that atomoxetine (10 μM) might act as an
agonist, antagonist, or allosteric modulator of GABAA recep-
tors was assessed by recording changes in either the resting
membrane potential of ventrobasal neurons associated with
GABAA receptor activity or the inhibitory postsynaptic poten-
tials (IPSPs) evoked by electrical stimulation of the GABA-
ergic inputs from the ventrobasal neurons of the reticular
thalamic nucleus (Zhang et al. 1997). Possible direct agonist
actions of atomoxetine (1 and 10 μM) were evaluated by
measuring changes in the resting membrane potential of neu-
rons before and during compound application. In these experi-
ments, selected concentrations of the GABAA receptor
agonist muscimol (1 μM), the GABAA receptor antagonist
bicuculline methochloride (10 μM), and the GABAA receptor
allosteric modulator pentobarbital (10 μM) were used as pos-
itive controls for agonist, antagonist, and potentiator activity,
respectively (Zhang et al. 1997).
Identical experiments were performed using nisoxetine hy-
drochloride (1 μM and 10 μM), another selective NE trans-
porter inhibitor, which is widely used in scientific research as a
standard selective NE reuptake inhibitor (Graham and Langer
1992). Results showed that atomoxetine (concentrations up to
10 μM) did not alter the IPSPs in ventrobasal neurons evoked
by electrical stimulation of the slice preparation (Fig. 1a).
However, in the same neurons, pentobarbital (10 μM) en-
hanced and bicuculline methochloride (10 μM) blocked
GABAA receptor-dependent IPSPs. Atomoxetine (1 μM) also
did not affect the membrane potential of ventrobasal neurons,
whereas muscimol (1 μM) hyperpolarized and bicuculline
methochloride (10 μM) blocked the hyperpolarization in these
same neurons (Fig. 1b). In addition, nisoxetine (1 μM and
10 μM) did not affect the membrane potential or IPSPs evoked
in ventrobasal neurons (data not shown). Collectively, these
data are consistent with in vitro binding studies and indicate
that atomoxetine does not have agonist, antagonist, or positive
allosteric actions at GABAA receptors.
In vivo animal studies
Rat neurotransmitter studies Bymaster et al. (2002) exam-
ined atomoxetine’s ability to block neurotransmitter
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depletion in a rat brain induced by monoamine transporter-
dependent neurotoxins. After rats were injected with the 5-HT
selective neurotoxin p-chloramphetamine hydrochloride
(p-CA), whole brain 5-HT concentrations were measured
using high-pressure liquid chromatography with electrochem-
ical detection (HPLC-EC). Results showed that atomoxetine
did not block depletion of rat brain 5-HT produced by p-CA,
indicating that atomoxetine does not significantly block 5-HT
transporters in vivo. To measure the ability of atomoxetine to
block NE uptake, the NE transporter-requiring neurotoxin
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochlo-
ride (DSP-4) was injected. Cortical NE concentrations were
measured 6 h after injection and analyzed using HPLC-EC.
Atomoxetine dose-dependently and potently blocked deple-
tion of NE in the rat hypothalamus by DSP-4, demonstrating
blockade of NE transporters in vivo.
In vivo microdialysis is an important technique, which
helps in the elucidation of the neurochemical profile, mech-
anism of action, and effects of several drugs on neurotrans-
mitter systems. This technique is used to measure drug-
induced changes in concentrations of neurotransmitters such
as acetylcholine, glutamate, GABA, and monoamines, and
their respective metabolites in the extracellular fluid in dis-
crete brain regions (Darvesh et al. 2011). In vivo micro-
dialysis studies in conscious rats (Bymaster et al. 2002)
showed that extracellular concentrations of NE in the
Table 1 Binding affinity of atomoxetine, other norepinephrine transporter inhibitors, and psychostimulants for the norepinephrine and dopamine
transporters compiled from several publications
Compound Ki (nM), mean Ratio DAT/NET
NET DAT
Unscheduled
Atomoxetine 3.7 (5.4,a 2.0b) 1,266 (1,451,a 1,080b) 342
Desipramine 2.4 (3.8,a 3.5,c 1.6,d 0.8b) >2,295 (>10,000,a 1,400,c 3,190b) >956
Scheduled
Methylphenidate 427 (339,a 514c) 46 (34,a 84,c 21e) 0.11
d-Amphetamine 257d 190e 0.74
Cocaine 2,100c 180 (120,c 240e) 0.09
Abbreviations: DAT = dopamine transporter; NET = norepinephrine transporter
a Bymaster et al. (2002)
b Tatsumi et al. (1997)
c Gatley et al. (1996)
d Cheetham et al. (1996)
e Pristupa et al. (1994)
a b
Fig. 1 Atomoxetine does not
affect a GABA-ergic IPSPs or b
the resting membrane potential
of ventrobasal thalamic neurons
in rat brain slices. Data points
reflect percentage of control in
a and mean ± SD in b.
* Significant difference from
control at p≤0.05.
Abbreviations: AUC = area
under the curve; GABA = γ-
aminobutyric acid (GABA);
IPSP = inhibitory postsynaptic
potential (IPSP); SD = standard
deviation
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prefrontal cortex were increased in a dose-dependent fashion
by atomoxetine, whereas the extracellular concentrations of
5-HT were not significantly altered by atomoxetine up to
3 mg/kg (intraperitoneal administration) in the brain regions
examined including the prefrontal cortex, NAc, and striatum.
Furthermore, atomoxetine increased extracellular concentra-
tions of DA to about the same magnitude as NE in the
prefrontal cortex; this was attributed to the finding that DA
in the prefrontal cortex is taken up by NE transporters (Di
Chiara et al. 1992). Higher doses of atomoxetine produced
greater and long-lasting increases in extracellular NE and DA
in the prefrontal cortex than lower doses.
However, atomoxetine did not increase extracellular DA in
the DA-rich NAc or striatum (Bymaster et al. 2002). In contrast
to atomoxetine, methylphenidate increased extracellular DA in
the NAc, an activity implicated in the reward and reinforcing
aspects of this drug (Table 2) (Kuczenski and Segal 1997,
1999). Similar results with atomoxetine microdialysis studies
were found in mice (Koda et al. 2010). The importance of
microdialysis studies is underscored in a recent review of
nonhuman primate imaging studies that found considerable
evidence supporting that drug-induced reinforcing effects,
DAToccupancy, and increases of extracellular DA levels were
closely related (Murnane and Howell 2011).
The immediate-early gene c-fos and its protein products
have been increasingly utilized as markers for neuronal
activation (Dragunow and Faull 1989; Morgan and Curran
1990; Robertson et al. 1994). Hence, the expression of the
neuronal activity marker Fos after atomoxetine administra-
tion was determined in several brain regions (Bymaster et al.
2002). In the atomoxetine studies, immunohistochemical lo-
calization of the Fos protein allowed the quantification of
activated cells in specific forebrain nuclei following vehicle
or atomoxetine administration. Atomoxetine significantly and
robustly increased the number of Fos-positive cells in the
prefrontal cortex (80±28 vehicle versus 296±26 atomoxetine,
p≤0.001), but not in the NAc or the striatum (Bymaster et al.
2002). In contrast, methylphenidate induced Fos expression in
the striatum of cats (Lin et al. 1996) and persistent c-fos in the
NAc and in the frontal cortex of the immature rat brain (Chase
et al. 2005). In another study, methylphenidate increased c-fos
expression predominately in the sensorimotor striatum, but not
in the NAc (Yano and Steiner 2005).
Thus, both the pattern of increase of DA in only the
prefrontal cortex as well as increased Fos expression in the
prefrontal cortex, but not in the NAc and striatum, indicates a
unique profile for atomoxetine compared with methylpheni-
date that may be related to atomoxetine’s low abuse potential.
Drug discrimination paradigm In drug discrimination mod-
els, animals are trained to discriminate effects of a particular
drug of abuse. Such models have also been used to indicate
how prominent the role of DA reuptake blockade is for the
abuse potential of a particular drug (Kleven et al. 1990;
Rowlett et al. 2007). A number of drug discrimination
studies have been conducted in rats (Terry et al. 1994),
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No self administration observed Doses greater than 0.03 mg/Kg
produced self-administration





90-mg dose increased “bad” and “sick” portions of VAS,
and LSD subscale on ARCI; not observed with lower
doses (20 mg and 45 mg)
40-mg dose increased





Partially substituted for methylphenidate (33 %–50 %);
stimulant-like drug effects were lower compared to







Abbreviations: ARCI =Addiction Research Center Inventory; ARS = Adjective Rating Scale; DA = dopamine; LSD = lysergic acid diethylamine;
NAc = nucleus acumbens; VAS = Visual Analog Scale
a Bymaster et al. (2002)
b Jones et al. (2000)
c Gasior et al. (2005)
d Heil et al. (2002)
e Lile et al. (2006)
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pigeons (Johanson and Barrett 1993; Sasaki et al. 1995;
Zhang and Barrett 1991), and monkeys (Kleven et al.
1990; Spealman 1995; Tidey and Bergman 1998) to evalu-
ate the subjective effects produced by atomoxetine and the
results overall suggest that atomoxetine has a low abuse
potential. Two discrimination studies in pigeons (Johanson
and Barrett 1993; Sasaki et al. 1995) reported the generaliza-
tion of atomoxetine with cocaine (1.0 or 1.7 mg/kg) or meth-
amphetamine (1.0 or 1.7 mg/kg). In both of these studies,
atomoxetine generalized at some dose but generalization
was not dose-responsive and was always accompanied by
reductions in response rate or a disruption of performance.
Cocaine itself produces full generalization and yet is devoid of
effects on response rate at the same doses (Terry et al. 1994).
Johanson and Barrett (1993) concluded that dopaminergic as
well as noradrenergic systems in the pigeons mediate the
discriminative stimulus effects of cocaine, while serotonergic
systems do not seem to be involved in this response. It was
also concluded that NE and DA reuptake inhibition and 5-HT
release mediate the discriminative stimulus effects of meth-
amphetamine (Johanson and Barrett 1993; Sasaki et al. 1995).
However, data from pigeons is of questionable value in ex-
trapolating to humans, as the pharmacology in this avian
species has been shown to differ from that of rodents and
primates. In rats and monkeys, when a very low dose of
cocaine is used as a training stimulus, atomoxetine has been
seen to occasionally generalize to cocaine (Spealman 1995;
Terry et al. 1994), but as the training dose of cocaine was
escalated to levels that produce frank psychomotor stimula-
tion, the generalization was lost. Furthermore, the generaliza-
tion sometimes observed with atomoxetine contrasts with that
of abused stimulants. While cocaine produced 100 % effects
in the rat drug discrimination model, atomoxetine did not
generalize to this extent (Terry et al. 1994). Atomoxetine
and nisoxetine (another NE reuptake inhibitor) substituted
for cocaine in these rats, suggesting NE involvement in the
discriminative stimulus effects of low doses of cocaine.
Moreover, the generalization was produced only at doses of
atomoxetine that had effects on other aspects of behavior
(response rates) that question the validity of data interpreta-
tion. It is noteworthy that the doses of atomoxetine and
nisoxetine that generalized to cocaine also produced substan-
tial decreases in the response rate to about 20 % of the control.
However, other drug discrimination studies using cocaine at
10 mg/kg as a training dose have shown that the NE reuptake
inhibitor desipramine, which has not demonstrated abuse po-
tential, substituted or partially substituted and bupropion fully
substituted for cocaine (Nicholson et al. 2009; Paterson et al.
2010). Selective 5-HT reuptake inhibitors did not substitute
for cocaine (Paterson et al. 2010; Terry et al. 1994).
In rhesus monkeys trained to discriminate cocaine, atom-
oxetine did not generalize to cocaine, whereas the indirect
DA agonists GBR 12909 (vanoxerine), mazindol,
nomifensine, and bupropion, each produced dose-related
increases in cocaine-appropriate responding, with complete
substitution for cocaine achieved at the highest doses of
each drug (Kleven et al. 1990).
Similar results are also seen in squirrel monkeys.
Atomoxetine produced some generalization at the lowest
training dose of cocaine but this did not hold at higher doses
of cocaine (Spealman 1995). Moreover, the pattern of
responding for atomoxetine observed in the Spealman
(1995) study was identical to the pattern observed for desi-
pramine (which lacks abuse potential) and nisoxetine.
Similar to cocaine, methamphetamine increases synaptic
DA levels by blocking reuptake; in addition, methamphet-
amine can diffuse through the neuronal membrane and
release cytoplasmic DA. In squirrel monkeys trained to
discriminate methamphetamine (0.3 mg/kg, IM) from sa-
line, a high dose of atomoxetine (17.8 mg/kg, IM) produced
full substitution in 1 of 3 monkeys, whereas lower doses
did not produce such an effect in any of the 3 monkeys
(Tidey and Bergman 1998).
In summary, a review of animal drug discrimination studies
indicates that atomoxetine will generalize to cocaine or meth-
amphetamine under certain conditions, like NE reuptake
inhibitors (e.g., imipramine and desipramine) lacking abuse
potential. These antidepressants also generalize to the training
drug under the same conditions that suggests the involvement
of noradrenergic systems in these discrimination models. In
monkeys, atomoxetine did not substitute for cocaine.
Generalization to cocaine-like effects seems to occur when a
low training dose of cocaine or a high dose of atomoxetine is
used for testing, which substantially decreases response rates.
The data demonstrating that atomoxetine, under some condi-
tions, can generalize to cocaine does not directly imply abuse
potential. Despite its different profiles of neurotransmitter
effects in the drug discrimination studies, atomoxetine produ-
ces a pattern of effects similar to that of tricyclic antidepres-
sants, drugs that have low abuse potential confirmed during
many years of clinical use and availability. The nonclinical
literature also documents a common subjective effect profile
for abused stimulants that maps onto their abuse and depen-
dence potential in man. In contrast, the nonclinical data in the
area has distinguished atomoxetine from that of the abused
stimulants, including methylphenidate. It was predicted from
this distinction that atomoxetine would be devoid of psycho-
motor stimulant-like abuse and dependence potential and
would therefore not be subject to drug diversion.
Self-administration in monkeys Atomoxetine was tested in
two separate animal self-administration models that are pre-
dictive of abuse potential in humans. In the first study (Wee
and Woolverton 2004), rhesus monkeys were prepared with
chronic intravenous catheters and trained to press a lever to
receive cocaine injections. Various doses of atomoxetine,
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methylphenidate, desipramine, and their vehicles were peri-
odically substituted for cocaine. A drug dose was considered
a positive reinforcer in any monkey if the number of injec-
tions it maintained in all test sessions was outside the 95 %
confidence interval for all vehicle test sessions. Cocaine and
methylphenidate clearly functioned as positive reinforcers,
whereas atomoxetine and desipramine did not. The second
study employed a choice paradigm (Gasior et al. 2005) in
which rhesus monkeys were trained to press one lever for
injections of either saline or drug, and another lever for the
delivery of food. Dose–effect functions were determined for
cocaine, methylphenidate, D-amphetamine, atomoxetine,
and desipramine. Saline availability was typically associated
with high rates of responding for food. In contrast, avail-
ability of cocaine, methylphenidate, or D-amphetamine at
doses greater than 0.03 mg/kg/injection produced >90 %
responding on the injection lever. No dose of atomoxetine or
desipramine maintained self-administration behavior on the
injection lever until doses were increased to levels that
disrupted overall behavioral functioning (Table 2) (Gasior
et al. 2005). As such, these results from two different, well-
controlled nonhuman primate self-administration models
suggest that atomoxetine lacks abuse potential.
Human studies
The results from three abuse potential studies in humans
provide valuable evidence to support the low drug abuse
potential of atomoxetine compared with other stimulant
drugs (summarized in Table 2). In the first study, physiological
and subjective effects of atomoxetine and methylphenidate
compared with placebo were assessed in a human laboratory
study (Heil et al. 2002). Sixteen nondependent, light drug
users (average age=20 years) participated in six experimental
sessions in which they received placebo, atomoxetine (20, 45,
90 mg) and methylphenidate (20, 40 mg) using a double-
blind, Latin square design. Assessments were conducted be-
fore drug administration and at 30, 60, 90, 120, 150, 180, and
240 min after dosing. In addition to blood pressure (BP) and
heart rate (HR), subjective drug effects were measured at each
assessment using computer-based versions of Visual Analog
Scales (VAS), the ARCI, and Adjective Rating Scales (ARS)
(Heil et al. 2002).
The results of this study indicated that relatively few subjec-
tive drug effects of atomoxetine were different from the placebo
(Heil et al. 2002). Specifically, the highest atomoxetine dose
(90 mg) significantly increased the VAS “bad” and “sick”
scores. Atomoxetine did not significantly affect scores on
any of the ARCI subscales, except for a peak effect on the
lysergic acid diethylamide subscale at the 90-mg dose. It could
be argued that atomoxetine doses were too low to produce
substantial subjective effects. However, doses were sufficient-
ly high to demonstrate significant and to some extent unpleas-
ant physiological effects. In contrast to atomoxetine,
methylphenidate increased many self-report measures sensi-
tive to stimulant effects, including the stimulant scales of the
ARS, the VAS, and the ARCI benzedrine, amphetamine, and
morphine–benzedrine subscales. Because this study of drug
effects in humans demonstrated that atomoxetine did not
engender pleasurable subjective effects, it provides evidence
that atomoxetine is unlikely to have abuse potential.
In the second study, Lile et al. (2006) examined the
discriminative stimulus and subjective effects of atomoxe-
tine in six subjects with recent histories of stimulant use.
After the subjects acquired the discrimination, they were
given test doses of methylphenidate (5 to 30 mg), atom-
oxetine (15 to 90 mg), D-amphetamine (2.5 to 15 mg),
triazolam (0.06 to 0.375 mg), and placebo. Subjective
effects questionnaires (ARS, Stimulant-Sensitive Adjective
Rating Scale, ARCI, and a locally developed Drug Effect
Fig. 2 Effects of placebo, desipramine (100 and 200 mg), methylphe-
nidate (90 mg), phentermine (60 mg), and atomoxetine (45, 90, and
180 mg) on the Drug Rating Questionnaire item “How much do you
like the effects you are feeling now?” Six-hour maximum scores
(Jasinski et al. 2008). Abbreviations: ATX = atomoxetine; DMI =
desipramine; MPH = methylphenidate; PHN = phentermine; SE =
standard error of the mean. Letters above the bars represent statistical
significance: p<0.05 vs. a placebo, b DMI 100 mg, c DMI 200 mg, d
MPH 90 mg, e PHN 60 mg, f ATX 45 mg, g ATX 90 mg, h ATX
180 mg
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Questionnaire [DEQ]), a performance task (Digit-Symbol
Substitution Task), and cardiovascular evaluations were also
completed. Methylphenidate and D-amphetamine increased
drug-appropriate responding and produced stimulant-like
subjective effects (e.g., increased ratings of “active/alert/e-
nergetic,” “stimulated,” “shaky,” and “jittery”) that were
significantly different from placebo on all six domains of
the DEQ. There was no significant difference between atom-
oxetine and placebo except for the DEQ domain “any ef-
fect” at the 90-mg dose, and for HR and BP effects
attributable to noradrenergic activity. Only the 90-mg atom-
oxetine dose significantly increased methylphenidate-
appropriate responding relative to placebo. Triazolam pro-
duced low, insignificant levels of drug-appropriate respond-
ing and sedative-like subjective effects. The authors suggest
that the subjective effects profile of atomoxetine, partially
overlapping with abused stimulants, and indicative of low
abuse potential may mean that atomoxetine could be useful
as a replacement therapy for stimulant abuse.
Lastly, in an inpatient study (Jasinski et al. 2008) that
included 46 subjects with experienced, stimulant-preferring
drug abuse history, examined the abuse potential of atomox-
etine (Fig. 2). Subjects received double-blind, single doses of
eight test drugs (placebo, 90 mgmethylphenidate, 60 mg of the
stimulant phentermine, 100 and 200 mg desipramine, and 45,
90, and 180 mg atomoxetine) using a balanced Latin square
design. The Drug Rating Questionnaire-Subject (DRQS) and
subscales of the ARCI data were collected for 24 h after each
dose. Six-hour maximum scores were compared using analysis
of variance. Methylphenidate and phentermine produced
stimulant-like effects and euphoria, with significant scores on
the DRQS “liking” subscale and the morphine-benzedrine,
amphetamine, and benzedrine ARCI subscales. None of the
doses of atomoxetine or desipramine produced stimulant-like
effects or euphoria as measured by these scales. In this popu-
lation of stimulant-preferring drug abusers, atomoxetine at
doses up to 180 mg was not a euphoriant and did not produce
stimulant-like subjective effects. Overall, the human laboratory
studies strongly suggest a low abuse potential of atomoxetine.
Other human studies
To date, there are no studies evaluating the abuse potential
of atomoxetine in patients with ADHD. However, atomox-
etine treatment in a double-blind placebo-controlled trial in
adult patients with ADHD and comorbid ethanol abuse/de-
penendence, resulted in improvement in ADHD symptoms
(Wilens et al. 2008b), which was significantly correlated
with reduced alcohol cravings (Wilens et al. 2011).
Further, the reduction in ADHD symptoms in the
atomoxetine-treated group was not altered despite relapse
to alcohol abuse. A post hoc analysis revealed that the
cumulative heavy drinking days did not decrease until after
ADHD symptoms improved and the adverse event profile
was not suggestive of abuse potential for atomoxetine
(Wilens et al. 2011).
Another approach is to study types of symptoms (e.g.,
dysphoria or depression, insomnia, irritability, frustration or
anger, anxiety, and restlessness) immediately following dis-
continuation as to whether they suggest a drug withdrawal
syndrome. Wernicke et al. (2004) evaluated the effects of
abrupt discontinuation of atomoxetine in four placebo-
controlled trials in children and adults with ADHD. Two
of those were identical studies in children involved 9 weeks
double-blind treatment followed by abrupt discontinua-
tion or 1 week of single-blind placebo treatment. The
other twowere identical studies in adults involved 9–10weeks
double-blind treatment followed by a 4-week double-blind
discontinuation phase where those on placebo comtinued on
placebo and those on atomoxetine were randomized to either
abrupt or tapered discontinuation. Atomoxetine was not asso-
ciated with an acute discontinuation syndrome and hence, may
be discontinued without risk of discontinuation-emergent ad-
verse effects (Wernicke et al. 2004; http://pi.lilly.com/us/
strattera-pi.pdf). The lack of discontinuation syndrome provides
further supporting evidence for the low-abuse potential of
atomoxetine.
Conclusions
The abuse potential evaluation for atomoxetine reviewed
here was comprehensive and involved preclinical and clin-
ical assessments including neuropharmaceutical character-
ization, receptor binding studies, animal behavioral studies
(reinforcing effects, discriminative effects, physical depen-
dence, and tolerance), and human pharmacology studies
(subjective effects, toxicity and performance impairement,
tolerance and physical dependence). Atomoxetine was not
placed under CSA, which includes the US FDA’s eight-
factor analysis of abuse potential for determination of con-
trol and scheduling of drugs prior to marketing.
Atomoxetine was approved for the treatment of patients
with ADHD as an uncontrolled and unscheduled medication
in contrast to methylphenidate and amphetamine, which are
placed under CSA and approved as schedule II (high phys-
ical or psychological dependence potential) drugs based on
the eight-factor analysis.
Data from the in vitro and in vivo preclinical studies suggest
that unlike stimulants (e.g., methylphenidate, amphetamines),
atomoxetine does not have appreciable abuse potential. Further,
atomoxetine was not associated with discontinuation-emergent
adverse events in patients with ADHD in clinical trials that are
suggestive of physical dependency.
Human abuse potential studies in atomoxetine were con-
ducted in subjects with histories of substance abuse, which
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is a standard procedure in the field. There is a growing body
of literature examining medication diversion and misuse
(Upadhyaya 2007; Wilens et al. 2008a). Evidence from
those studies as well as from the postmarketing surveillance
over the past 10 years has not indicated that atomoxetine is
misused or diverted (Upadhyaya 2007; Wilens et al. 2008a).
Collectively, the broad experimental research summa-
rized in this review supports that atomoxetine lacks abuse
potential. As such, atomoxetine offers an alternative and
efficacious nonstimulant treatment option for patients with
ADHD.
Implications for future abuse potential research
It is evident that a comprehensive approach is needed for the
evaluation of abuse potential of a psychoactive drug and that
the results of a single study cannot be relied on to adequate-
ly characterize the potential for abuse. The eight-factor
analysis conducted by the FDA seems like a reasonable first
step that was able to predict lack of abuse potential with
atomoxetine. Given that significant resources are required to
conduct a program addressing the eight factors, more spe-
cific guidance, e.g., conditions under which such a program
is needed, the type of required studies, animal models need-
ed to be examined, types of comparators needed in human
studies would be helpful.
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